Moreover, today, several new drugs are being developed for the treatment of hypertension that will interfere with aldosterone actions such as non-steroidal mineralocorticoid receptor antagonists, centrally acting aminopeptidase inhibitors or aldosterone synthase inhibitors (71). This evidence concerns the gene CPQ and hypertensive disorder.